January 2025—Maine Molecular Quality Controls announced the launch of the Birlinn BCR-ABL1 p210 IS panel C230, intended to monitor the detection and quantification of BCR-ABL1 (p210) fusion gene using molecular test systems. The panel, with assigned values traceable to the World Health Organization, allows calculation of a conversion factor necessary to express quantification results (M-bcr transcript of BCR-ABL1 p210 relative to the ABL1 transcript) according to the International Scale. The company also launched the Birlinn BCR-ABL1 p210 IS control panel C240, intended for use as an assayed external quality control to monitor the performance of in vitro laboratory nucleic acid detection and quantification of BCR-ABL1 (p210) fusion gene.
The Birlinn HH Panel G203 is intended for in vitro use as a quality control to monitor the analytical performance of test systems used in the qualitative detection of the HFE H63D, S65C, and C282Y variants most commonly associated with hereditary hemochromatosis. The panel is provided as a nonextractable control with copy numbers of HFE DNA similar to that of extracted human whole blood samples.
Maine Molecular Quality Controls, 207-885-1072